Celltrion Healthcare (Formerly Known As Celltrion)
1000 Marina Boulevard
About Celltrion Healthcare (Formerly Known As Celltrion)Celltrion Healthcare conducts the worldwide marketing, sales and distribution of biological medicines developed by Celltrion, Inc. through an extensive global network that spans more than 120 different countries. Celltrion Healthcare’s products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US Food and Drug Administration (FDA) cGMP guidelines and the EU GMP guidelines.
CEO: Jung Jini
Please click here for clinical trial information.
Tweets by Celltrion
80 articles with Celltrion Healthcare (Formerly Known As Celltrion)
Celltrion Healthcare launches Remsima™ SC, the world's first subcutaneous formulation of infliximab in Canada, for the treatment of people with rheumatoid arthritis
Celltrion Healthcare Canada Limited announced the launch of Remsima™ SC, the world's first subcutaneous formulation of infliximab in Canada for the treatment of adult patients with rheumatoid arthritis.
Celltrion Receives FDA Emergency Use Authorization for Point of Care Antigen Rapid Test Kit – DiaTrust™ COVID-19 Ag Rapid Test
DiaTrust™ received the U.S. Food and Drug Administration Emergency Use Authorization approval for their COVID-19 Point of Care antigen rapid test kit, DiaTrust™.
Celltrion Group announces positive top-line efficacy and safety data from global Phase II/III clinical trial of COVID-19 treatment candidate CT-P59
CT-P59 (40mg/kg) treated patients reported reduced progression rates to severe COVID-19 by 54% for patients with mild-to-moderate symptoms and 68% for moderate patients aged 50 years and over
Celltrion Submits Application for Conditional Marketing Authorisation of Its COVID-19 Treatment Candidate CT-P59 to the Korean MFDS
Celltrion submitted today an application for Conditional Marketing Authorisation of CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate to the Korean Ministry of Food and Drug Safety (MFDS) Celltrion plans to submit Emergency Use Authorisation (EUA) to the U.S. FDA and Conditional Marketing Authorisation (CMA) to theEuropean Medicines Agency (EMA) for CT-P59 in the coming months
As if attempting to steal hard-won research wasn’t bad enough, hackers are now hitting people where it really hurts – with e-documents containing malicious code embedded in false offers of employment.
Further sharpens Takeda’s focus on ‘fast tracking’ patient access to highly innovative medicines for complex and rare diseases in Asia Pacific and the Emerging Markets
Celltrion Completes Acquisition of Primary Care (PC) Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company Limited
USD 278 million deal signed to secure 18 small molecule pharmaceutical product brand patents, trademarks, permits and sales rights in 9 Asia Pacific countries including South Korea
11/9/2020It was relatively quiet in terms of COVID-19-related clinical trials, but there was still quite a bit of news for trials involving other indications. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 26, 2020.
Celltrion Launches Human Clinical Trial of Potential COVID-19 Antiviral Antibody Treatment Following Positive Pre-Clinical Results
Celltrion Group announced the launch of its Phase I human clinical trial investigating a potential antiviral antibody treatment for patients with COVID-19.
Celltrion Healthcare Receives Positive CHMP Opinion for an Additional Five Indications for Remsima® SC Including for Use in Inflammatory Bowel Disease and Ankylosing Spondylitis
Celltrion Healthcare announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended expanding the existing marketing authorisation for the subcutaneous formulation of Remsima® in an additional five indications: for the treatment of patients with ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and psoriasis.
Celltrion Announces Positive Pre-clinical Results for COVID- 19 Antiviral Antibody Treatment, Showing Improvement in Recovery Time
Pre-clinical data for Celltrion’s antiviral antibody treatment candidate demonstrate a 100-fold reduction in viral load of SARS-CoV-2 (COVID-19), as well as improvement in lung lesions
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 1, 2020.
Celltrion Completes Neutralisation Test on Candidate Monoclonal Antibodies (mAbs) for COVID-19 Antiviral Antibody Treatment
Celltrion Group announced that the company has successfully selected the most potent antibody candidates to neutralise SARS-CoV-2, the virus causing COVID-19.
Celltrion Group announced its successful transition to the second phase of development for an antiviral treatment to fight the novel coronavirus pandemic, following the completion of the first phase of securing 300 different types of antibodies that bind to the antigen last month.
Celltrion Accelerates Development of COVID-19 Antiviral Treatment and Aims to Launch Rapid Self-testing Kit
Celltrion Group announced key milestones in its efforts to fight the 2019 novel coronavirus pandemic.
Teva and Celltrion Healthcare Announce U.S. Availability of HERZUMA® (trastuzumab-pkrb) for Injection
Teva and Celltrion Healthcare Announce U.S. Availability of HERZUMA ® (trastuzumab-pkrb) for Injection
Celltrion’s chairman Jung Jin Seo announced at last week’s JP Morgan Healthcare Conference the company’s strategy for the next decade.
FDA Approved TemixysTM, a two-drug single-tablet antiretroviral (ARV) for HIV Treatment, will be Celltrion’s first branded product to be commercialized in 4Q 2019 through its direct-customer partnerships
Celltrion Healthcare Receives CHMP Positive Opinion for Novel Subcutaneous Formulation of CT-P13 (biosimilar infliximab) for the Treatment of People With Rheumatoid Arthritis
Celltrion Healthcare today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for CT-P13 SC for marketing authorisation in the European Union (EU) in people with rheumatoid arthritis (RA).